2019-12-16 11:37:00 Mon ET
technology antitrust competition bilateral trade free trade fair trade trade agreement trade surplus trade deficit multilateralism neoliberalism world trade organization regulation public utility current account compliance
America and China cannot decouple decades of long-term collaboration in trade, finance, and technology. In recent times, some economists claim that China may attempt to decouple decades of trade collaboration with the U.S. due to better tech supremacy on the eastern front. Several other economists further claim that China may try to revamp financial services and technological innovations well ahead of America.
Goldman Sachs chief strategy officer Stephanie Cohen indicates that these claims are overdone. In fact, Goldman continues to pursue fresh business opportunities in China after at least 2 decades of investment bank penetration there. In recent years, Goldman Sachs invests $60 million to bail out many depositors in Chinese brokerage firm Hainan Securities, which offers rich political connections in the one-party regime. Moreover, Goldman Sachs receives official approval from the China Securities Regulatory Commission (CSRC) to boost its equity stakes in Goldman Sachs Gao Hua Securities to the maximum cap of 51% from 33%. With managerial control over the joint venture, Goldman Sachs retains a key competitive advantage over its rivals such as JPMorgan Chase, UBS, and Nomura etc. This competitive edge empowers Goldman Sachs to further invest in Sino-American trade, finance, and technology in light of the new bilateral fair trade agreement.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be
2019-06-25 10:34:00 Tuesday ET

Investing in stocks is the best way for people to become self-made millionaires. A recent Gallup poll indicates that only 37% of young Americans below the a
2018-11-23 09:39:00 Friday ET

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma. After the U.S. midterm electio
2018-01-13 08:39:00 Saturday ET

The Economist digs deep into the political economy of U.S. government shutdown over 3 days in January 2018. In more than 4 years since 2014, U.S. government
2017-05-07 06:39:00 Sunday ET

While the original five-factor asset pricing model arises from a quasi-lifetime of top empirical research by Nobel Laureate Eugene Fama and his long-time co
2019-07-03 11:35:00 Wednesday ET

U.S. regulatory agencies may consider broader economic issues in their antitrust probe into tech titans such as Amazon, Apple, Facebook, and Google etc. Hou